Three-Statement Breakdown
REVENUE UP
Revenue rose 8.2% year over year to $12.5B, and carried a 4.8% net margin.
REVENUE
+8.2%
12,484
GROSS PROFIT
—
—
NET INCOME
+10.0%
605
EPS (DILUTED)
+10.2%
$15.39
| Income statement | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | YoY | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
|
8,176 | 8,899 | 9,361 | 9,524 | 10,676 | 11,454 | 11,535 | 12,484 | +8.2% |
| Research & development |
|
(25) | (23) | (31) | (34) | (40) | (35) | (27) | (26) | -3.7% |
| SG&A |
|
(871) | (788) | (904) | (898) | (924) | (1,022) | (973) | (977) | +0.4% |
| Operating income |
|
951 | 736 | 799 | 513 | 565 | 781 | 535 | 657 | +22.8% |
| Interest expense |
|
(58) | (70) | (114) | (89) | (102) | (95) | (95) | (105) | +10.5% |
| Income tax |
|
(135) | (134) | (114) | (78) | (140) | (172) | (93) | (172) | +84.9% |
| Net income |
|
836 | 549 | 696 | 544 | 579 | 681 | 550 | 605 | +10.0% |
| EPS (diluted) |
|
$19.09 | $13.26 | $17.14 | $13.50 | $14.44 | $17.07 | $13.96 | $15.39 | +10.2% |
Click a line to select it — Enter or the EXPAND pill folds out its quarter-by-quarter history.
No comparable bridge for this view yet.
↹ CLICK A LINE TO SELECT · ⌘F FIND LINE ITEM
SRC 10-Q FILED 2026-07-30 ↗